廣告
香港股市 已收市
  • 恒指

    18,335.32
    -95.07 (-0.52%)
     
  • 國指

    6,556.10
    -31.67 (-0.48%)
     
  • 上證綜指

    3,005.44
    -12.61 (-0.42%)
     
  • 道指

    38,834.86
    +56.76 (+0.15%)
     
  • 標普 500

    5,487.03
    +13.80 (+0.25%)
     
  • 納指

    17,862.23
    +5.21 (+0.03%)
     
  • Vix指數

    12.56
    +0.08 (+0.64%)
     
  • 富時100

    8,235.33
    +30.22 (+0.37%)
     
  • 紐約期油

    81.70
    +0.13 (+0.16%)
     
  • 金價

    2,353.20
    +6.30 (+0.27%)
     
  • 美元

    7.8037
    -0.0025 (-0.03%)
     
  • 人民幣

    0.9298
    +0.0007 (+0.08%)
     
  • 日圓

    0.0490
    -0.0001 (-0.28%)
     
  • 歐元

    8.3702
    -0.0171 (-0.20%)
     
  • Bitcoin

    66,334.23
    +1,034.33 (+1.58%)
     
  • CMC Crypto 200

    1,378.70
    -3.97 (-0.29%)
     

Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate

Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate

Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes.

The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo.

The weight loss achieved with CT-388 was clinically meaningful, with a mean placebo-adjusted weight loss of 18.8% (p-value < 0.001).

At week 24, 100% of CT-388 treated participants achieved a weight loss of over 5%, 85% achieved over 10%, 70% achieved over 15%, and 45% achieved over 20%.

廣告

The treatment was well tolerated, with mild to moderate gastrointestinal-related adverse events being the most common, consistent with the incretin class of medicines that CT-388 belongs to.

All participants with a pre-diabetes status at baseline became normoglycemic after 24 weeks of CT-388 treatment, whereas the glycemic status of participants treated with placebo remained largely unchanged during this period.

CT-388 belongs to the class of incretin-based medicines that aim to regulate blood sugar and reduce appetite.

It selectively targets and activates two specific receptors in the body, GLP-1 and GIP, which integrate nutrient-derived signals to control food intake, energy absorption and assimilation.

An additional cohort from the ongoing placebo-controlled Phase 1b trial of CT-388 will evaluate obese patients (BMI>30 kg/m2) with type 2 diabetes over a 12-week treatment duration.

Roche expects data from this additional cohort in the second half of 2024.

In December, Roche agreed to acquire a privately held obesity company, Carmot Therapeutics, for $2.7 billion in cash. Additionally, Carmot’s equity holders are entitled to receive payments of up to $400 million depending on achieving certain milestones.

Once-a-week injection CT-388 is Carmot’s obesity candidate.

Photo by Vidmir Rais via Pixabay

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.